2015 in review: The year’s top ten cases


2015 in review: The year’s top ten cases


There were some major IP court decisions in 2015. WIPR reflects on a busy year.

1  A song and dance over biosimilars

By now the words ‘patent dance’ should need little introduction and one of the biggest intellectual property disputes of 2015 looks likely to run into 2016.

In July, the US Court of Appeals for the Federal Circuit ruled in Amgen v Sandoz that biosimilar applicants can opt out of the dance, a process allowing parties to address any patent claims while a biosimilar drug is being approved by the US Food and Drug Administration. Sandoz, which was sued by Amgen over its biosimilar version of Amgen’s drug Neupogen (filgrastim), has since launched the product.

Supreme Court, trademark, Lindt, Fibria, FRAND, Nestle, Robin Thicke, Marvin Gaye, Eldorado, Marvel v Kimble, CJEU, Huawei v ZTE, SEP, Starbucks, Myriad,